Dokument: TNFalpha-Polymorphismus bei Patienten mit Sepsis und Schilddrüsenkarzinomen

Titel:	TNFalpha-Polymorphismus bei Patienten mit Sepsis und Schilddrüsenkarzinomen
URL für Lesezeichen:	https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=11095
URN (NBN):	urn:nbn:de:hbz:061-20090819-104039-0
Kollektion:	Dissertationen
Sprache:	Deutsch
Dokumententyp:	Wissenschaftliche Abschlussarbeiten » Dissertation
Medientyp:	Text
Autor:	Rossbach, Christiane [Autor]
Dateien:	[Dateien anzeigen] Adobe PDF [Details] 602,4 KB in einer Datei [ZIP-Datei erzeugen] Dateien vom 27.04.2009 / geändert 27.04.2009
Beitragende:	PD Dr. med. Gross-Weege, Wilhelm [Gutachter] Prof. Dr. MacKenzie, Colin [Gutachter]
Stichwörter:	TNFalpha-Polymorphismus,Sepsis,Schilddrüsenkarzinome
Dewey Dezimal-Klassifikation:	600 Technik, Medizin, angewandte Wissenschaften » 610 Medizin und Gesundheit
Beschreibung:	Das Zytokin Tumornekrosefaktor a (TNFa) hat einen entscheidenden Anteil an der Entwicklung schwerer Komplikationen, wie septischer Schock und Multiorganversagen nach Entwicklung einer Sepsis. Eine Assoziation des TNF2-Allels mit einem erhöhten TNF a Spiegel und einer höheren Mortalitätsrate wurde in zahlreichen Studien beschrieben. Auch bei verschiedenen Karzinomen ist TNFa neben anderen Mediatoren durch die Steuerung des programmierten Zelltods, Apoptose, am Verlauf eines Karzinoms beteiligt. Er kann sowohl zytotoxisch als auch metastasenfördernd wirken. Außerdem gilt er verschiedentlich als guter Marker für die Prognose eines Karzinoms. In meiner Arbeit sollen die Fragen beantwortet werden, ob der –308 G/A TNF a Polymorphismus beziehungsweise ein gehäuftes Auftreten des TNF2 Allels (-308A Allel) eine Aussage über die Schwere einer Sepsis zulässt und ob ein gehäuftes Auftreten des –308 TNF a Polymorphismus bei Schilddrüsenkarzinomen beobachtet werden kann. Zu diesem Zweck wurden 54 Sepsis-Patienten und 31 Patienten mit Schilddrüsenkarzinom auf den –308 TNF a Polymorphismus mittels PCR untersucht und mit einer Kontrollgruppe von 75 Gesunden verglichen. Es stellte sich heraus, dass in der Gruppe der Sepsis-Patienten keine signifikanten Unterschiede in der Verteilung des TNF a Polymorphismus für die Allele TNF1 (-308G Allel) und TNF2 (-308A Allel) gegenüber der Kontrollgruppe gefunden werden konnten. In der Gruppe der Schilddrüsenkarzinompatienten hingegen konnte eine Signifikanz bezüglich des häufigeren Auftretens des TNF2 (-308A Allels) festgestellt werden. Die Ergebnisse in der Intensiv-Gruppe zeigen, dass die erhöhten TNF a Spiegel, die bei Erkrankten häufig gemessen werden können, nicht unmittelbar mit dem –308 TNF a Polymorphismus in Zusammenhang stehen müssen, sondern auch in der Verlinkung des TNF a zum Beispiel mit dem HLA-Molekül begründet sein kann. Zum anderen weisen die Ergebnisse der Karzinom-Gruppe auf einen möglichen Zusammenhang zwischen dem –308 TNF a Polymorphismus und dem Vorkommen eines Schilddrüsenkarzinoms hin, welcher als Hinweis auf die Anfälligkeit, ein Schilddrüsenkarzinom zu entwickeln, dienen könnte.
Quelle:	[1] Abraham E., M.P. Glauser, Th. Butler, J. Garbino, D. Gelmont, P.F. Laterre, K. Kudsk, H.A.Bruining, Ch. Otto, E. Tobin, Ch. Zwingelstein, W. Lesslauer, A. Leighton; p55 Tumor necrosis Factor Receptor Fusion Protein in the Treatment of Patients with severe Sepsis and septic Shock; JAMA may 1997, 277 (19) 1531-8 [2] Abraham E., R. Wunderink, H. Silverman, T.M. Perl, St. Nasraway. H. Levy, R. Bone, R.P. Wenzel, R. Balk, R. Allred, J.E. Pennington, J.C. Wherry; Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrom, JAMA 1995, 273 (12) 934-41 [3] Abraham L.J., M. A. H. French, R. L. Dawkins; Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-a ; Clin Exp Immunol 1993; 92: 14-18 [4] Aderka D, Englemann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kushtai G; Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients; Cancer Res. 1991 Oct 15;51 (20): 5602-7 [5] Allen Ruth D.; Polymorphism of the human TNF-alpha Promotor- random variation or functional diversity?; Molecular immunology 36 (1999) 1017-1027 [6] Alves-Filho José Carlos, Claudia Benjamim, Beatriz Martins Tavares-Murta, Fernando Q Cunha; Failure of the neutrophil migration toward infectious focus in severe sepsis :a critical event for the outcome of this syndrome; Mem Inst Oswaldo Cruz; Rio de Janeiro, 2005, Vol. 100 (Suppl. 1): 223-226 [7] Aosasa S., S. Ono, H. Mochizuki, H. Tsujimoto, Sh. Osada, E. Takayama, S. Seki, H. Hiraide; Activation of Monocytes and endothelial cells depends on the severity of surgical Stress; World Journal of surgery,24, 2000, 10-16 [8] Asai K, Hiki N, Mimura Y, Ogawa T, Unou K, Kaminishi M; gender differences in cytokine secretion by human peripheral blood mononuclear cells: role of estrogen in modulating LPS-induced Cytokine secretion in an ex vivo septic model; Shock 2001; 16(5): 340-3 [9] Astiz M.E., E.C. Rackow; Septic Shock; The Lancet,1998; Vol. 351,S.1501-1505 [10] Azmy Iman AF, Saba P Balasubramanian, Anthony G Wilson, Timothy J Stephenson, Angela Cox, Nicola J Brown, Malcom WR Reed; Role of tumour necrosis factor gene polymorphisms (-308 and –238) in breast cancer susceptibility and severity; Breast Cancer Res 2004, 6: R395-R400 [11] Balkwill F., F. Burke, D. Talbot, J. Tavernier, R. Osborne, St. Naylor, H. Durbin, W. Fiers; Evidence for Tumour necrosis factor/cachectin Production in Cancer;The Lancet, Nov. 28,1987;1229-1232 [12] Barber M.D.;J.J. Powell, S.F. Lynch, N.J. Gough, K.C.H. Fearon& J.A. Ross; Two polymorphisms of the tumor necrosis factor gene do not influence survival in pancreatic cancer; Clinical and Experimental Immunology 1999;117: 425- 429 [13] Baud L., J. Cadranel, G. Offenstadt, L. Luquel, B. Guidet, P. Amstutz; Tumor Necrosis Factor and Septic Shock, Crit Care Med, 1990,Vol.18, No.3, S.349-350 [14] Behnia Mehrdad, Kent A. Robertson, William J. Martin; Role of Apoptosis in host defence and pathogenesis of disease; Chest 2000; 117:1771-1777 [15] Berman Kevin S., Udit N. Verma, Gwyndolen Harburg, John D. Minna, Melanie H. Cobb, Richard B. Gaynor; Sulindac enhances tumor necrosis factor-a mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kB; Clinical cancer research, Feb. 2002; Vol. 8, 354-360 [16] Bernal William, Peter Donaldson, James Underhill, Julia Wendon , Roger Williams; Tumor necrosis factor genomic Polymorphism and outcome of Acetaminophen (paracetamol)-induced acute liver failure; Journal of Hepatology 1998; 29: 53-59 [17] Beutler B., D. Greenwald, J.D. Hulmes, M. Chang, Y.-C. E. Pan, J. Mathison, R. Ulevitch, A. Cerami; Identity of tumor necrosis factor and macrophage-secreted factor cachectin, Nature, Aug. 1985, 316, 552-54 [18] Bone RC, members of the American college of chest physicians/society of critical care medicine consensus conference committee: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874 [19] Bone Roger C.; Sir Isaac Newton, sepsis, SIRS and CARS; Crit Care Med 1996, Vol 24, No 7;1125-1128 [20] Book M., M. Petersen, E.U. Schade und F.Stüber; ein Polymorphismus des TNFa Promotors bei Patienten mit schwerer Sepsis; Intensivmedizin und Notfallmedizin, Band 32, Suppl.1 (1995) [21] Borish Larry C., John W. Steinke; Cytokines and chemokines; J Allergy Clin Immunol, 2003 Feb; 111 (Suppl 2):460-75 [22] Bougacha-Elleuch N, Rebai A, Mnif M, Makni H, Bellassouad M, Jouida J, Abid M, Hammadi A; Analysis of MHC genes in a Tunisian isolate with autoimmune thyroid disease: implication of TNF -308 gene polymorphism; J Autoimmun. 2004 Aug;23(1):75-80 [23] Bouma G., J.B.A. Crusius, M. Oudkerk Pool, J.J. Kolkman, B.M.E. von Blomberg, P.J. Kostense, M.J. Giphart, G.M.Th. Schreuder, S.G.M. Meuwissen, A.S. Pena; Secretion of tumor necrosis factor a and Lymphotoxin a in relation to Polymorphism in the genes and HLA-DR alleles. Relevance for Inflammatory Bowel disease; Scand. J. Immunol. 43, 456-463, 1996 [24] Bouma G., B. Xia, J.B.A. Crusius, G. Bioque, I. Koutroubakis, B.M.E. von Blomberg, S.G.M. Meuwissen, A.S. Pena; Distribution of four polymorphisms in the tumor necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD); Clin Exp Immunol 1996;103:391-396 [25] Bras M., B. Queenan, S.A. Susin ; Programmed cell death via mitochondria : different modes of dying ; Biochemistry (Moscow), Vol. 70, No. 2, 2005, pp. 231-239 [26] Brinkman B.M.N., T.W.J. Huizinga, S.S. Kurban, E.A. van der Velde, G.M.Th. Schreuder, J.M.W. Hazes, F.C. Breedveld und C.L. Verweij; Tumour necrosis factor a gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease?; British Journal of Rheumatology 1997; 36:516-521 [27] Burdon Dan, Peter Zabel; Akutphase-Reaktion und Immunkompetenz in Sepsis und SIRS; Wien Klin Wochenschr (2002) 114 (Suppl 1): 1-8 [28] Burmester, Pezutta; Taschenatlas der Immunologie, Thieme 1998 [29] Cabrera M., M.-A. Shaw, C. Sharples, H. Williams, M. Castes, J. Convit, J.M. Blackwell; Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis; J. Exp. Med 182 Nov. 1995, 1259-1264 [30] Calabrese L.H., N. Zein und D. Vassilopoulos; Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection; Ann Rheum Dis 2004; 63;18-24 [31] Call Douglas Ruben, Jean Ann Nemzek, Samuel John Ebong, Gerald Lee Bolgos, David Eric Newcomb, Daniel George Remick; Ratio of local to systemic chemokine concentrations regulates neutrophil recruitment; American journal of pathology; Vol. 158, No. 2, Feb. 2001:715-721 [32] Carbó N., P. Costelli, L. Tessitore, G.J. Bagby, F.J. López-Soriano, F.M. Baccino, J.M. Argilés; Anti-Tumor necrosis factor a treatment interferes with changes in lipid metabolism in a tumor cachexia model; Clinical Science, 1994,87,349-355 [33] Carroll M. C., P. Katzmann, E. M. Alicot, B. H. Koller, D. E. Geraghty, H. T. Orr, J.L. Strominger, T. Spies; Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes, Proc. Natl. Acad Sci. USA 84,1987;8535-8539 [ 34] Carswell E.A., L.J. Old, R.L. Kassel, S. Green, N. Fiore, B. Williamson; An endotoxin-induced serum factor that causes necrosis of tumors, Proceedings of the Nat. Acad. Of Sciences of the U.S.A., Sep. 1975, 72(9): 3666-70 [35] Chen G., R. Wilson, S. H. Wang, H. Z. Zheng, J. J. Walker, J. H. Mc Killop; Tumour necrosis factor-alpha (TNF-a) gene polymorphism and expression in pre-eclampsia; Clin Exp Immunol, 1996;104; S. 154-159 [36] Chorinchath B. B., L-Y. Kong, L. Mao, R. E. McCallum; Age-associated differences in TNF-a and nitric oxide production in endotoxic mice;The journal of Immunology, 1996, 156: S. 1525- 1530 [37] Chouchane L., Slim Ben Ahmed, Sami Baccouche, Sami Remadi; Polymorphism in the tumor necrosis factor-a promotor region and in the heat shock Protein 70 genes associated with malignant Tumors; American cancer society, October 1997, Volume 80/ No.8 1489-1496 [38] Clark Ian A., Lisa M. Alleva, Alison C. Mills and William B. Cowden; Pathogenesis of Malaria and Clinically Similar Conditions; Clinical Microbiology Reviews, July 2004,Vol. 17, No. 3:p 509-539 [39] Cohen J., MB, FRCP; Jean Carlet; for the INTERSEPT study group; An international, multicenter, placebocontrolled trial of monoclonal antibody to human tumor necrosis factor – a in patients with sepsis; Critical care medicine Sep 1996, 24 (9) 1431-40 [40] Coley W.B.; The treatment of malignant tumors by repeated inoculations of erysipelas, with a report of ten original cases; American Journal of medicine and science,105:487-511, 1893 [41] Costa A., Fernandez-Real JM., Vendrell J., Broch M., Casamitjana R., Ricart W., Conget I.; Lower rate of tumor necrosis factor-a - 863A allele and higher concentration of tumor necrosis factor-a receptor 2 in first degree relatives of subjects with type 2 diabetes; Metabolism. 2003 Aug; 52(8): 1068-71 [42] Cullinan Amy E., Curtis R. Brandt; Cytokine induced apoptosis in human retinoblastom cells; Molecular vision 2004; 10:315-22 [43] Cusack James C., Jr.; Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver; annals of surgical oncology, 2002, 10(8):852-862 [44] D‘Alfonso S, Momigliano Richiardi P. A polymorphic variation in a putative regulation box of the TNF promotor region. Immunogenetics 1994; 39: 150-4 [45] Das BK, Mishra S, Padhi PK, Manish R, Tripathy R, Sahoo PK, Ravindran B; Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults; Trop Med Int Health. 2003 Aug; 8(8):680-4 [46] Davies F.E., S.J. Rollinson, A.C. Rawstron, E. Roman, St. Richards, M. Drayson, J.A. Child, G.J. Morgan; High-producer haplotypes of tumor necrosis factor a are associated with an increased risk of myeloma and have an improved progression-free survival after treatment; Journal of clinical oncology, Aug. 2000, Vol.18, No. 15, 2843-2851 [47] Demeter J., F.Porzsolt, St. Rämisch, M. Schmid, G. Messer; Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in hairy cell leukaemia; British Journal of Haematology, 1997; 97, S.132-134 [48] Demeter J., F. Porzsolt, St. Rämisch, D. Schmidt, M. Schmid, G. Messer; Polymorphism of the tumor necrosis factor-alpha and lymphotoxin- alpha genes in chronic lymphocytic leukaemia; British Journal of Haematology, 1997; 97, S.: 107-112 [49] Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierobe L, Stephens S, Ney UM, Sopwith M.;CDP571, a humanized antibody to human tumor necrosis factor-a : safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group; Crit Care Med 1995 Sep; 23(9): 1461-9 [50] Dhainaut J.-F., J.P. Mira and F. Brunet; Investigational therapy of sepsis: Anti-TNF, IL-1ra, Anti-PAF and G-CSF; Clinical trials for the treatment of sepsis. Springer (1995);267-282 [51] Diao Hongyan, Masashi Kohanawa, Yimin, Hirofumi Nakajima, Yuichiro Sato, Tomonori Minagawa, Akio Nakane; Lipopolysaccharide triggers invasive streptococcal disease in mice through a tumour necrosis factor-a dependent mechanism; Immunology 2002, 105, pp344-349 [52] Dimmeler S., H. Troidl; Mediatorensystem und Sepsis; Chirurg 1995; 66:S.2-10 [53] Dinarello CA; Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock; Chest 1997; 112:321-9 [54] Dinarello CA; Proinflammatory Cytokines; Chest 2000; 118:503-8 [55] Diodato MD, Knoferl MW, Schwacha MG, bland KI, Chaudry ICH; gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis; Cytokine, 2001 May 7; 14(3): 162-169 [56] Dolcet X, Llobet D, Pallares J, Matias-Guiu X; NF-kappaB in development and progression of human cancer; Virchows Arch. 2005 May;446(5):475-82 [57] Duan Lian, Masaru Aoyagi, Masashi Tamaki, Yoshikazu Yoshino, Takashi Morimoto, Hiroaki Wakimoto, Yasuhiko Nagasaka, Kimiyoshi Hirakawa, Kikuo Ohno, Kiyotaka Yamamoto; Impairment of both apoptotic and cytoprotectiv signalings in glioma cells resistant to the combined use of Cisplatin and Tumor necrosis factor a; Clinical Cancer Research, Jan. 1, 2004; Vol. 10, 234-243 [58] Fabian T.C., Croce M.A., Fabian M.J., Trenthem L.L., Yockey J.M., Boscarino R., Proctor K.G.; Reduced tumor necrosis factor production in endotoxin- spiked whole blood after trauma: Experimental results and clinical correlation; Surgery, July 1995;63-72 [59] Fabris M, Di PE, D’Elia A, Damante G, Sinigaglia L, Ferraccioli G; Tumor necrosis factor-a gene polymorphism in severe and mild-moderate rheumatoid arthritis; J Rheumatol. 2002 Jan; 29(1):29-33 [60] Feldmann M., Bondeson J., Brenan F.M., Foxwell B.M.J., Maini R.N.; The rationale for the current boom in anti-TNFa treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFa and minimise hazards?; Ann Rheum Dis 1999; 58 (Suppl I)I27-I31 [61] Ferrajoli Alessandra, Michael J. Keating, Taghi Manshouri, Francis J. Giles, Amanda Dey, Zeev Estrov, Charles A. Koller, Razelle Kurzrock, Deborah, A. Thomas, Stefan Faderl, Susan Lerner, Susan O’Brien, Maher Albitar; The clinical significance of tumor necrosis factor-a plasma level in patients having chronic lymphocytic leukemia; Blood; 15 Aug 2002, Vol. 100, No.4:pp 1215-1219 [62] Fiers W., Tumor necrosis factor, Characterization at the molecular, cellular and in vivo level;FEBS letters, 1991,Vol.285,No.2, S 199- 212. [63] Fisher C.J., Opal S.M., Dhainaut J.F., et al. (1993); Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis; Crit Care Med 21; 318-327 [64] Fitzgibbon Jude, D. Grenzelias, J. Matthews, T. A. Lister, R.K. Gupta; Tumor necrosis factor polymorphisms and susceptibility to follicular lymphoma; British Journal of Haematology; Nov/1999, 107, 388-391 [65] Fraunberger P., A.K. Walli, D. Seidel; Zytokinanalytik; Internist 2001,42; S 35-46 [66] Galley H.F., N.R. Webster; The immuno-inflammatory cascade; British Journal of Anaesthesia 1996; 77:11-16 [67] Gavrilescu L. Christian, Eric Y. Denkers; Apoptosis and the Balance of Homoeostatic and Pathologic Responses to Protozoan Infection; Infection and Immunity, Nov. 2003, p 6109-6115 [68] Gemsa, Kalden, Resch; Immunologie, Thieme, 1991 [69] Girardin E., G.E. Grau, J-M. Dayer, P. Roux-Lombard, The J5 Study group, P.-H. Lambert; Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious Purpura, New Engl. J. Med, 319 (1988) 397-400 [70] Gordon Melita A., Emia Oppenheim, Nicola J. Camp, Francesco S. di Giovine, Gordon W. Duff and Dermot Gleeson; Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor a Promotor region; Journal of hepatology 1999;31:242-247 [71] Grau G.E., T.E. Taylor, M.E. Molyneux, J.J. Wirima, P. Vassalli, M. Hommel, P.H. Lambert; 1989; Tumor necrosis factor and disease severity in children with falciparum malaria.; New England Journal of medicine, 320, 1586-1591 [72] Gray P.W., B.B. Aggarwal, C.V. Benton, T.S. Bringman, W.J. Henzel, J.A. Jarrett, D.W. Leung, B. Moffat, P. Ng, L.P. Svedersky, M.A. Palladino, G.E. Nedwin; Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor necrosis activity; Nature, Dec.1984, Vol 312, 721-724 [73] Griffith Thomas S., Wilson A. Chin, Glenn C. Jackson, David H. Lynch, Marek Z. Kubin; Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells; The journal of immunology, 1998, 161:2833-2840 [74] Grutters Jan C., Hiroe Sato, Panagiotis Pantelidis, Anna L. Lagan, Deirdre S. McGrath, Jan-Willem J. Lammers, Jules M. M. van den Bosch, Athol U. Wells, Roland M. du Bois, Kenneth I. Welsh; Increased frequency of the uncommon tumor necrosis factor –857T Allele in british and dutch patients with sarcoidosis; Am J Respir Crit Care Med, 2002, Vol. 165: pp 1119-1124 [75] Hamblin AS: Cytokines and Cytokine Receptors. Oxford, IRL Press, 1993 [76] Harriman G., Harper L.K., Schaible T.F.; Summary of clinical trials in rheumatoid arthritis using infliximab, an anti- TNFa treatment; Ann Rheum Dis 1999; 58 (Suppl I) I61-I64 [77] Heesen Michael, Dagmar Kunz, Martina Wessiepe, Tom van der Poll, Aeilko H. Zwinderman, Brunhilde Blomeke; Rapid genotyping for tumor necrosis factor a (TNF-a ) –863 C/A promotor polymorphism that determines TNF-a response; Clinical chemistry, 2004, 50, No.1:226-228 [78] Herbein Georges, William A. O’Brien; Tumor necrosis factor (TNF)-a and TNF receptors in viral pathogenesis; P.S.E.B.M. 2000, Vol 223:241-257 [79] Hirayama Kenji; Genetic factors associated with development of cerebral malaria and fibrotic schistosomiasis; The Korean Journal of Parasitology; Dec. 2002, Vol.40, No.4:165-172 [80] Ho Sy, Wang YJ, Chen HL, Chen CH, Chang CJ, Wang PJ, Chen HH, Guo HR; Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2-Allele of the –308 tumor necrosis factor-a Promotor gene; Cancer causes control., 2004 Sep;15(7):657-63 [81] Hoch R.C., Rodriguez R., Manning Th., Bishop M., Mead P., Shoemaker W.C., Abraham E., Effects of accidental trauma on cytokine and endotoxin production; Crit Care Med; 1993,Vol 21 No.6, 839-845 [82] Höflich C., H-D Volk; Immunmodulation in der Sepsis; Chirurg 2002, 73: 1100-1104 [83] Holmes Cheryl L., James A. Russell, Keith R. Walley; Genetic Polymorphisms in Sepsis and Septic Shock: Role in Prognosis and Potential for Therapy; Chest 2003; 124; 1103-1115 [84] Huang DeRen, Ritva Pirskanen, Georg Matell, Ann Kari Lefvert; Tumor necrosis factor a polymorphism and secretion in myasthenia gravis; Journal of Neuroimmunology 94 (1999);165-171 [85] Huang S-L., C-H. Su, S-C. Chang; Tumor necrosis factor a gene polymorphism in chronic bronchitis, Am. J. Respir. Crit. Care Med. 1997; 156, 1436- 1439 [86] Huizinga T.W., R.G. Westendorp, E.L. Bollen, V. Keijsers, B.M. Brinkman, J.A. Langermans, F.C. Breedveld, C.L. Verweij, L. van der Gaer, L. Dams, J.B. Crusius, A. Garcia-Gonzales, B.W. van Oosten, C.H. Polman, A.S. Pena; TNF-a promotor polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients; Journal of Neuroimmunology 1997 Feb;72(2):149-153 [87] Jacob Chaim O., Zdenka Fronek, Gail D. Lewis, May Koo, John A. Hansen, Hugh O. McDevitt; Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor a: Relevance to genetic predisposition to systemic lupus erythematosus; Proc. Natl. Acad. Sci. USA, February 1990, Vol.87, 1233-1237 [88] Juszczynski Przemyslaw, Ewa Kalinka, Jaques Bienvenu, Grzegorz Woszczek, Maciej Borowiec, Marek Kowalski, Ewa Öech-Maranda, Lucile Baseggio, Bertrand Coiffier, Gilles Salles und Krzysztof Warzocha; Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome; Blood, 15 Oct 2002, Vol.100, No.8:pp3037-3040 [89] Kast Richard E., Eric L. Altschuler; Anti-apoptosis function of TNFa in chronic lymphocytic leukaemia: lessons from Crohn`s disease and the therapeutic potential of bupropion to loxer TNFa; Arch Immunol Ther Exp, 2005, 53, 143-147 [90] Kawakami M., A. Cerami; Studies of endotoxin-induced decrease in lipoprotein lipase activity, J. Exp. Med., Sep. 1981, 154, 631-37 [91] Keane Maccon M., Seth A. Ettenberg, Marion M. Nau, Edward K. Russell, Stan Lipkowitz; Chemotherapy augments TRAIL-induced apoptosis in breast cell lines; Cancer research 59, Feb 1, 1999; 734-41 [92] Keller, Immunologie und Immunpathologie; Thieme 1994 [93] Keller R., Immunologie und Immunopathologie; Thieme 1995 [94] Kern P., C.J. Hemmer, J. Van Damme, H.J. Gruss, M. Dietrich; 1989; Elevated tumor necrosis factor a and interleukin-6 serum levels as markers for complicated plasmodium falciparum malaria.; American Journal of medicine,1989 Aug; 87(2): 139-143. [95] Kitakata Hidekazu, Yoko Nemoto-Sasaki, Yutaka Takahashi, Toshikazu Kondo, Masayoshi Mai, Naofumi Mukaida; Essential roles of Tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of Colon 26 cells, Cancer research, November 15, 2002; 62, 6682-87 [96] Kobayashi Scott D., Jovanka M. Voyich, Christopher Burlak, Frank R DeLeo; Neutrophils in the innate immune response; Arch Immunol Ther Exp; 2005, 53, 505-517 [97] Kornelisse R.F., J.A. Hazelzet, H.F. J. Savelkoul, W.C.J. Hop, M.H. Suur, A.N.J. Borsboom, I.M. Risseeuw-Appel, E. van der Voort, R. de Groot; The relationship between Plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock; Journal of infectious diseases; 1996; 173:1148-56 [98] Kox W.J., T. Volk, S. N. Kox, H.-D. Volk; Immunmodulatory therapies in sepsis; Intensive care Med (2000) 26: S124-128 [99] Kroeger K.M., K.S. Carville, L.J. Abraham; The –308 Tumor necrosis factor a Promotor polymorphism effects transcription; Molecular Immunology,1997, Vol.34, No. 5,391-399 [100] Küçükaycan Mehmet, Michiel Van Krugten, Herman-Jan Pennings, Tom WJ Huizinga, Wim A Buurman, Mieke A Dentener, Emiel FM Wouters; Tumor necrosis factor-a +489G/A gene polymorphism is associated with chronic obstructive pulmonary disease; Respir Res 2002, Vol. 3, No.1: 29, Epub 2002 Nov. 29 [101] Kwiatkowski D., C. A. W. Bate, I. G. Scragg, P. Beattie, I. Udalova, J. C. Knight; The malaria fever response - pathogenesis, polymorphism and prospects for intervention; Annals of Tropical Medicine and Parasitology, 1997; Vol. 91, No.: 5, S. 533-542 [102] Kwiatkowski D., Molyneux M.E., Stephens S, Curtis N, Klein N, Pointaire P, Smit M, Allan R, Brewster DR, Grau GE, et al. Anti-TNF Therapy inhibits fever in cerebral malaria; Q J Med 1993 Feb;86(2):91-8 [103] Lindsey J.K.; Modelling Frequency and Count Data; 1995, Oxford University Press [104] Loppnow H.; Zytokine: Klassifikation, Rezeptoren, Wirkungsmechanismen, Internist, 2001, 42, S. 13-27 [105] Louis E., M. Peeters, D. Franchimont, L. Seidel, F. Fontaine, G. Demolin, F. Croes, P. Dupont, L. Davin, S. Omri, P. Rutgeerts, J. Belaiche; Tumor necrosis factor gene polymorphism in Crohn`s disease: influence on disease behaviour?; Clinical and experimental Immunology 2000;119:64-68 [106] Louis E., J. Satsangi, M. Roussomoustakaki, M. Parkes, G. Fanning, K. Welsh, D. Jewell; Cytokine gene Polymorphisms in inflammatory bowel disease; Gut 1996; 39: 705-710 [107] Low AS, Azmy I, Sharaf , Cannings C, Wilson AG; Association between two tumour necrosis factor intronic polymorphisms and HLA allels; Eur J Immunogenet. 2002 Feb; 29(1):31-4 [108] Lu CC, Sheu BS, Chen TW, Yang HB, Hung KH, Kao AW, Chuang CH, Wu JJ; Host TNFa -1031 and –863 Promotor single nucleotide polymorphisms determine the risk of benign ulceration after H-Pylori infection; Am J Gastroenterol. 2005 Jun; 100(6): 1274-82 [109] Lu Liang-Ping, Xiang-Wang Li, Ying Liu, Guo-Chang Sun, Xue-Ping Wang, Xi-Lin Zhu, Quan-You Hu, Hui Li; Association of –238G/A Polymorphism of tumor necrosis factor-a gene Promotor region with outcomes of hepatitis B virus infection in Chinese han population; World J Gastroenterol 2004; 10(12):1810-1814 [110] Marks J.D., C.B. Marks, J.M. Luce, A.B. Montgomery, J. Turner, C.A. Mietz, J.F. Murray; Plasma Tumor necrosis factor in patients with septic Shock; Am. Rev. Respir. Dis. 1990; 141: 94-97 [111] Marrosu M. G., M. R. Murru, G. Costa et al. ,Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and –DR4 alleles; American Journal of Hum Genet 1997;61:454-457 [112] McGuire W., A.V.S. Hill, C.E.M. Allsopp, B.M. Greenwood, D. Kwiatkowski; Variation in the TNF-a promotor region associated with susceptibility to cerebral malaria, Nature, Vol 371, Oct. 1994, 508-511 [113] Mc Manus R., A.G. Wilson, J. Mansfield, D.G. Weir, G.W. Duff, D. Kelleher; TNF2, a polymorphism of the tumour necrosis-a gene Promotor, is a component of the celiac disease major histocompatibility complex haplotype, Eur. J. Immunol. 1996.26: 2113-2118 [114] Meager A.; Cytokines, Open university press, 1990 [115] Meduri G Umberto; Clinical review: A paradigm shift: the bidirectional effect of inflammation on bacterial growth. Clinical implications for patients with acute respiratory distress syndrome; Critical care; Feb 2002,Vol 6,No. 1:24-29 [116] Mira J.-P., A. Cariou, F. Grall, Chr. Delclaux, M.-R. Losser, F. Heshmati, Chr. Cheval, M. Monchi, J.-L. Teboul, F. Riché, G. Leleu, L. Arbibe, A. Mignon, M. Delpech, J.-F. Dhainaut, Association of TNF2, a TNF-a Promotor Polymorphism, With Septic Shock Susceptibility and Mortality, JAMA, 1999, Vol.282, No.6, S.561-568 [117] Mitsiades C S, V Poulaki, N Mitsiades; The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer; Journal of Endocrinology (2003) 178, 205-216 [118] Moldawer L.L., C. Drott, K. Lundholm; Monocytic production and plasma bioactivities of interleukin-1 and tumour necrosis factor in human cancer; European Journal of Clinical Investigation (1988) 18, 486-492 [119] Mysliwska Jolanta, Ewa Bryl, Piotr Trzonkowski, Andrzej Mysliwski; Compensatory effect of TNFa on low natural killer activity in the elderly; Acta Biochemica Polonica, No.2/2000, Vol.47; 301-311 [120] Nadel S., M. J. Newport, R. Booy, M. Levin; Variation in the Tumor Necrosis Factor-a Gene Promotor Region May Be Assoziated with Death from Meningococcal Disease, 1996; The Journal of Infectious Diseases, 174: S. 878-880 [121] Nasraway Stanley A; The Problems and Challenges of Immunotherapy in Sepsis; Chest 2003; 123; 451-459 [122] Nedwin G. E., S. L. Naylor, A.Y. Sakaguchi, D. Smith, J. Jarret-Nedwin, D. Pennica, D.V. Goeddel, P. W. Gray; Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization; Nucleic.Acids.Res.1985;13,6361-6373 [123] Neilson D, Kavanagh JP, Rao PN; Kinetics of circulating TNF-a and TNF soluble receptors following surgery in a clinical model of sepsis; Cytokine, 1996 Dec.; 8(12): 938-43 [124] Neugebauer E., S. Dimmeler, H. Troidl; Mediatorensystem und Sepsis; Chirurg 1995; 66:S.2-10 [125] Old L.J.; Tumor necrosis Factor (TNF), Science, Nov. 1985, 230, 630-32 [126] Ono S, Tsujimoto H, Hiraki S, Takahata R, Kinoshita M, Mochizuki H, Sex differences in cytokine production and surface antigen expression of peripheral blood mononuclear cells after surgery; Am J Surg 2005 Sep; 190(3): 439-44 [127] Opal Steven M., DePalo Vera A.; Anti-inflammatory Cytokines; Chest 2000; 117: 1162-72 [128] Pang Xuan-Ping, Nathan S. Ross, Minha Park, Guy J.F. Julliard, Thomas M. Stanley , Jerome M. Hershman; Tumor necrosis factor-a activates nuclear factor k and induces Manganous Superoxide Dismutase and Phosphodiesterase mRNA in human papillary thyroid Carcinoma Cells; The Journal of Biological Chemistry 1992; Vol.267, No.18, Issue June 25;12826-12830 [129] Pang XP, Ross NS, Hershman JM; Alterations in TNF-a signal transduction in resistant human papillary thyroid carcinoma cells; Thyroid 1996 Aug;6(4):313-7 [130] Pang XP, Yoshimura M, Wang J, Dubinett SM; TNFa-induced antiprolifaration is not dependent on the autocrine action of TGF-b 1 in a thyroid cancer cell line; Lymphokine Cytokine Res. 1994 Apr;13(2):93-7 [131] Papadakis Konstantinos A., Stephan R. Targan; Tumor necrosis factor: Biology and therapeutic inhibitors; Gastroenterology 2000; 119:1148-1157 [132] Pastor IJ., Laso F.J., Romero A., Gonzalez-Sarmiento R.; -238 G>A polymorphism of tumor necrosis factor-a gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men; Alcohol Clin Exp Res. 2005 Nov; 29(11): 1928-31 [133] Paterson R.L., N.R. Webster; Sepsis and systemic inflammatory response syndrome; J. R. Coll. Surg. Edinb., 45, June 2000, 178-182 [134] Pennica D., G.E. Nedwin, J.S. Hayflick, P.H. Seeburg, R. Derynck, M.A. Palladino, W.J. Kohr, B.B. Aggarwal, D.V. Goeddel; Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin; Nature, Dec. 1984, Vol 312, 724-729 [135] Petersen M., F. Bokelmann, U.F. Schade, F. Stüber; TNFB 2 Homozygote sind Risikopatienten in der schweren Sepsis; Intensivmedizin und Notfallmedizin, Band 32,Supplement 1 1995 [136] Pfeffer K, Matsuyama T, Kundig T.M. et al. (1993); Mice deficient for the 55-kd TNF receptor are resistant to endotoxin shock, yet succumb to L. monocytogenes infection. Cell 73:457-467 [137] Philchenkov A; Caspase: potential targets for regulating cell death; J. Cell. Mol. Med. Vol. 8, No.4, 2004 pp 432-444 [138] Porteu Francoise, Carl Nathan; Shedding of tumor necrosis factor receptors by activated human Neutrophils; J. Exp. Med, Aug. 1990, Vol. 172, 599-607 [139] Prince Lynne R., Lucy Allen, Elizabeth C. Jones, Paul G. Hellewell, Steven K. Dower, Moira K.B. Whyte, Ian Sabroe; The role of Interleukin-1ß in direct and Toll-like receptor 4-mediated neutrophil activation and survival: American Journal of pathology, Vol. 165, No. 5, Nov. 2004: 1819-26 [140] Przemyslaw Juszczynski, Ewa Kalinka, Jaques Bienvenu, Grzegorz Woszczek, Maciej Borowiec, Marek Kowalski, Ewa Öech-Maranda, Lucile Baseggio, Bertrand Coiffier, Gilles Salles und Krzysztof Warzocha; Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome; Blood, 15 Oct 2002, Vol.100, No.8:pp3037-3040 [141] Pschyrembel, 257. Auflage, 1994 [142] Reinhart K., Wiegand C., Kaul M.(1994); Anti-TNF strategies with monoclonal antibody. Preliminary results with the specific monoclonal antibody MAK 195F. Intensive Care Med 20 (Suppl.1): S151 [143] Reinhart K., C. Wiegand-Löhnert, F. Grimminger, M. Kaul, St. Withington, D. Treacher, J. Eckart, Sh. Willatts, C. Bouza, D. Krausch, F. Stockenhuber, J. Eiselstein, L. Daum, J. Kempeni; Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibodyfragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebocontrolled, dose – ranging study, Critical care medicine, May 1996, 24 (5) 733-42 [144] Rink L., H. Kirchner; Recent Progress in the Tumor necrosis Factor – a Field, Int Arch Allergy Immunology 1996;111:199-209 [145] Rogers Richard J., Joan M. Monnier, Harry S. Nick; Tumor necrosis factor a selectively induces MnSOD expression via Mitochondria-to-nucleus signalling, whereas Interleukin-1 b utilizes an alternative pathway; the journal of biological chemistry, Vol.276, No.23 Issue June 8 2001, pp:20419-27 [146] Rolando N., Ellis A., Groote DD., Wendon J., Williams R., Correlation of serial cytokine levels with progression to coma (grade IV) in patients with acute liver failure; Hepatology 1995, 22 Suppl. 366 [147] Rudwaleit M, Tikly M, Khamashta M, Gibson K, Klinke J, Hughes G, Wordsworth P; Interethnic differences in the association of tumor necrosis factor Promotor polymorphisms with systemic lupus erythematosus; J Rheumatol. 1996 Oct; 23(10): 1725-8 [148] Saarinen U.M., E.-K. Koskelo, A-M. Teppo, M. A. Siimes; Tumor necrosis factor in children with Malignancies; Cancer Research 50,592-595,Feb/1990 [149] Sandmand M., Bruunsgaard H., Kemp K., Andersen-Ranberg K., Schroll M., Jeune B.; High circulating levels of tumor necrosis factor- a in centenarians are not associated with increased production in T Lymphocytes; Gerontology, 2003 May-June; 49(3): 155-60 [150] Schäffer M., H.-D. Becker; Immunregulation der Wundheilung;Chirurg,1999; 70: S 897-908 [151] Scuderi Ph., K.S. Lam, K.J. Ryan, E. Petersen, K.E. Sterling, P.R. Finley, C. G. Ray, D.J. Slymen, S.E. Salmon; Raised serum levels of tumour necrosis factor in parasitic infections; The Lancet, Dec. 1986,1364-1365 [152] Selby P.J., S. Hobbs, C. Viner, E. Jackson, I.E. Smith, T.J. McElwain; Endogenous Tumour necrosis factor in cancer patients, Lancet Feb/27,1988;483 [153] Skapenko Alla, Gerald U. Niedobitek, Joachim R. Kalden, Peter E. Lipsky, Hendrik Schulze-Koops; Generation and Regulation of Human Th1-Biased Immune Response In Vivo: A Critical Role for IL-4 and IL-10; The Journal of Immunology; 2004, 172: 6427-34 [154] Skeie G.O., J.P. Pandey, J.A. Aarli, N.E. Gilhus; TNFA and TNFB Polymorphisms in myasthenia gravis; Arch neurol, Apr. 1999, Vol 56, 457-461 [155] Skoog Tiina, Ferdinand M van’t Hooft, Bengt Kallin, Stefan Jovinge, Susanna Boquist, Jan Nilsson, Per Eriksson, Anders Hamsten; A common functional polymorphism (C®A substitution at position –863) in the promotor region of the tumour necrosis factor-a (TNF-a ) gene associated with reduced circulating levels of TNF-a; Human Molecular Genetics, 1999, Vol. 8, No.8, 1443-1449 [156] Sotgiu St., M. Pugliatti, C. Serra, G. Rosati, A. Dolei, M.G. Marrosu; Tumor necrosis factor2 allel does not contribute to increase tumor necrosis factor a production in Sardinian multiple Sclerosis,1999,Annals of Neurology Vol 46,No 5, 799-800 [157] Stack W. H., S. D. Mann, A. J. Roy, P. Heath, M. Sopwith, J. Freeman, G. Holmes, R. Long, A. Kamm; Randomised controlled trial of CDP571 antibody to tumour necrosis factor-a in Crohn´s disease; Lancet 1997; 349: S. 521-524 [158] Stadler J., C.D. Heidecke, H. Bartels, B. Holzmann, H. Wagner, J.R. Siebert, Immunsuppression und Sepsis, Chirurg 1995; 66: S. 11-16 [159] Stirnadel H.A., M. Stöckle, I. Felger, T. Smith, M. Tanner, H-P. Beck; Malaria infection and morbidity in infants in relation to genetic polymorphisms in Tanzania; Tropical Medicine and international health; 1999, Vol.4, No. 3, 187-193 [160] Stüber F., I.A. Udalova, M. Book, L. N. Drutskaya, D. V. Kuprash, R. L. Turetskaya, F. U. Schade, S. A. Nedospasov; -308 Tumor necrosis Factor (TNF) Polymorphism is not Associated With Survival in Severe Sepsis and is Unrelated to Lipopolysaccharide Inducubility of the Human TNF Promotor; Journal of Iinflammation, 1996; 46; S. 42-50 [161] Stüber F., M. Petersen, F. Bokelmann, U.Schade; A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-a concentrations and outcome of patients with severe sepsis; Crit. Care Med. 1996, Vol.24, No.3; S 381-384 [162] Suarez A; Lopez P, Mozo L, Gutierrez C; Differential effect of IL 10 and TNFa genotypes on determining susceptibility to discoid and systemic Lupus erythematosus; Ann Rheum Dis. 2005 Nov;64(11): 1605-10 [163] Tanaka Atsushi; Stefano Quaranta, Alberto Mattalia, Ross Coppel, Floriano Rosina, Michael Manns, M. Eric Gershwin; The tumor necrosis a correlates with progression of primary biliary cirrhosis ;Journal of hepatology, 1999; 30, 826-829 [164] Tang Gau-Jun, Song-Lih Huang, Huey-Wen Yien, Wie-Shone Chen, Chin-Wen Chi, Chew-Wun Wu, Wing-Yiu Lui, Jen-Hwey Chiu, Tak Yu Lee; Tumor necrosis factor gene polymorphism and septic shock in surgical infection, in: Crit Care Med 2000, Vol. 28, No. 8, S. 2733-2736 [165] Thompson CB; Apoptosis in the pathogenesis and treatment of disease; Science, 1995 Mar 10;267(5203):1456-62 [166] Tobon GJ, Correa PA, Gomez LM, Anaya JM; Lack of association between TNF –308 Polymorphism and the clinical and immunological characteristics of systemic lupus erythematosus and primary Sjogren’s syndrome; Clin Exp Rheumatol. 2005 May-Jun: 23(3): 339-44 [167] Tracey K.J., St.F. Lowry, The Role of Cytokine Mediators in Septic Shock,Adv.Surg,1990; 23, S. 21-56 [168] Tracey K.J., S. Morgello, B. Koplin, T.J. Fahey III, J. Fox, A. Aledo,K. R. Manogue, A. Cerami; Metabolic Effects of Cachectin/ Tumor Necrosis Factor Are Modified by Site of Production;J. Clin. Invest, 1990; Vol.86: S 2014-2024 [169] Tracey K.J., A. Cerami; Tumor necrosis factor: A Pleiotropic Cytokine and Therapeutic Target; Annu. Rev. Med. 1994; 45, S. 491- 503 [170] Tracey K.J., A. Cerami; Tumor necrosis factor: An updateed review of is biology, Crit Care Med,1993, Vol.21,No.10: S.415-422 [171] Tsuchiya N, Tokushige K, Yamaguchi N, Hasegawa K, Hashimoto E, Yamauchi K, Shiratori K; Influence of TNF-Gene polymorphism in patients with acute and fulminant hepatitis; J Gastroenterol. 2004 Sep; 39(9):859-66 [172] Uauy R, Solomons N, Diet, nutrition, and the life-course approach to cancer prevention; J. Nutr. 2005 Dec;135(12 Suppl):2934S-2945S [173] Uglialoro A.M., D. Turbay, P.A. Pesavento, J.C. Delgado, F.E. McKenzie, J.G. Gribben, D. Hartl, E.J. Yunis, A.E. Goldfeld; Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor a gene promotor; Tissue Antigens 1998: 52:359-367 [174] van der Poll T., J.A. Romijn, E. Endert, J.J.J. Borm, H.R. Büller, H.P. Sauerwein; Tumor necrosis factor mimics the metabolics response to acute infection in healthy humans, The American Physiological Society 1991,E457-E465 [175] van Hensbroek Boele, E. Onyiorah, S. Jaffar, G. Schneider, A. Palmer, J. Frenkel, G. Enwere, S. Forck, A. Nusmeijer, S. Bennett, B. Greenwood, D. Kwiatkowski; 1996; A trial of artemether or quinine in children with cerebral malaria; New England Journal of medicine; 335, 69-75. [176] Van Kooten C., Rensink I., Aarden L., van Oers R.; Cytokines and intracellular signals involved in the regulation of B-CLL proliferation; Leuk. Lymphoma, 1993, 12, 27-33 [177] van Noesel Max M, Saskia van Bezouw, Gajja S. Salomons, P. A. Voute, Rob Pieters, Steve B. Baylin, James G. Herman, Rogier Versteeg; Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing Ligand decoy receptors DcR1 and DcR2 is associated with dense Promotor Hypermethylation; Cancer Research 62, April 1, 2002;2157-2161 [178] van Zee K.J., Kohno T., Fischer E., et al. (1992) TNF soluble receptors circulate during experimental and clinical inflammation and can protect against excessive TNF in vitro and in vivo; Proc Natl Acad Sci USA 89: 4845-4849 [179] van Zee Kimberly J., Tadahiko Kohno, Eva Fischer, Craig S. Rock, Lyle L. Moldawer, Stephen F. Lowry; Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo; Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 4845-4849, June 1992 [180] Waage Anders, Nina Liabakk, Egli Lien, Jon, Lamvik, Terje Espevik; p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia; Blood, Vol.80, No.10 (November 15), 1992:pp 2577-2583 [181] Wagener Christoph; Einführung in die molekulare Onkologie; Thieme 1995 [182] Wang C-Y, Cusack JC, Liu R, Baldwin ASJ; Control of inducible chemoresistance: enhanced antitumor efficacy via increased apoptosis by inhibition of NF-k B. Nat Med 1999;5:412-7 [183] Warzocha Krzysztof, Patricia Ribeiro, Jacques Bienvenu, Pascal Roy, Carole Charlot, Dominique Rigal, Bertrand Coiffier, Gilles Salles; Genetic Polymorphisms in the tumor necrosis factor locus influence Non-Hodgkin`s lymphoma outcome; Blood, Vol. 91, No. 10 (May 15), 1998:3574-3581 [184] Wattavidanage J., R. Carter, K.L.R.L. Perera, A. Munasingha, S. Bandara, D. McGuinness, A.R. Wickramasinghe, H.K. Alles, K.N. Mendis, S. Premawansa; TNF alpha2 marks high risk of severe disease during Plasmodium falciparum malaria and other infections in Sri Lankans; Clin Exp. Immunol 1999; 115: 350-355 [185] Weitkamp J.H., F.Stüber, P. Bartmann; Pilot study assessing TNF-Gene polymorphism as a prognostic marker for disease progression in neonates with sepsis; Infection 28, 2000, No.2, 92-96 [186] Welte T.; Zytokine und obstruktive Atemwegserkrankungen, Internist, 2001; 42,S: 64-74 [187] Westendorp R.G.J., J.A. Langermans, T.W. Huizinga, C.L. Verweij, A. Sturk; 1997; Genetic influence on cytokine production and fatal meningococcal disease., Lancet, 349, 170-173 [188] Wihlborg Christel, Jan Sjöberg, Monica Intaglietta, Ulla Axdorph, Eva K .Pisa and Pavel Pisa; Tumor necrosis Factor-a cytokine Promotor gene polymorphism in Hodgkin`s disease and chronic lymphocytic leukaemia; British Journal of Haematology 1999,104,346-349 [189] Wilson AG, di Giovine FS, Blakemore AIF, Duff GW.; Single base polymorphism in the human Tumor Necrosis Factor (TNF) a gene detectable by NCOI restriction of PCR product. Hum Mol Gen 1992;1:353 [190] Wilson A.G., J.A. Symons, T.L. McDowell, H.O. McDevitt, G.W. Duff; Effects of a polymorphism in the human tumor necrosis factor a Promotor on transcriptional activation; Proc. Natl. Acad. USA, April 1997, Vol.94, 3195-3199 [191] Wilson AG, di Giovine FS, Duff GW: Genetics of tumor necrosis factor–a in autoimmune, infectious and neoplastic disease. J Inflamm 1995; 48:1-12 [192] Wilson A.G., N. de Vries, F. Pociot, F. S. di Giovine, L. B. A. van der Putte, G. W. Duff; An allelic polymorphism within the human tumor necrosis factor a Promotor region is strongly assoziated with HLA A1, B8 and DR3 allels; J. Exp. Med. 1993, Vol. 177; S.: 557- 560 [193] Zeerleder S., Ch. Caliezi, M. Redondo, J. Devay, W.A. Wuillemin; Aktivierung des plasmatischen Kaskadensystems bei Sepsis: Rolle von C1-Inhibitoren; Schweiz Med Wochenschrift, 1999; 129:1410-1417 [194] Zheng C., Huang D., Bergenbrant S., Sundblad A., Österborg A., Björkholm M. Holm G., Yi Q.; Interleukin 6, tumor necrosis factor a, interleukin 1b and interleukin 1 receptor antagonist Promotor or coding gene polymorphisms in multiple myeloma; British journal of haematology 2000, 109,39-45
Lizenz:	Urheberrechtsschutz
Fachbereich / Einrichtung:	Medizinische Fakultät
Dokument erstellt am:	19.08.2009
Dateien geändert am:	27.04.2009
Promotionsantrag am:	06.07.2008
Datum der Promotion:	06.10.2008